Marshall Wace, LLP Allogene Therapeutics, Inc. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $587,388 - $1.1 Million	185,296 Added 427.48%	228,642 $724,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $1.77 Million - $2.64 Million	-391,674 Reduced 90.04%	43,346 $215,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $2.14 Million - $3.57 Million	435,020 New	435,020 $2.15 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $129,959 - $217,607	12,593 New	12,593 $136,000
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $7.26 Million - $14.5 Million	-948,624 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $6.46 Million - $12.1 Million	492,033 Added 107.76%	948,624 $14.2 Million
Q2 2021 Aug 13, 2021	BUY	$23.49 - $35.8 $10.7 Million - $16.3 Million	456,591 New	456,591 $11.9 Million
Q2 2020 Aug 13, 2020	SELL	$18.39 - $54.04 $2.43 Million - $7.13 Million	-132,006 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $384,423 - $596,046	-21,099 Reduced 13.78%	132,006 $2.57 Million
Q4 2019 Feb 14, 2020	BUY	$24.82 - $31.4 $3.8 Million - $4.81 Million	153,105 New	153,105 $3.98 Million
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $509,771 - $644,096	-19,524 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $1.08 Million - $1.31 Million	-42,118 Reduced 68.33%	19,524 $525,000
Q1 2019 May 14, 2019	BUY	$24.82 - $32.54 $1.53 Million - $2.01 Million	61,642 New	61,642 $1.78 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.